淡江大學覺生紀念圖書館 (TKU Library)

系統識別號 U0002-2507201315313800
中文論文名稱 一新穎5,7-Dihydroxy-3’,4’-Diaminoflavone抑制HER2表現並抑制HER2過表現人類卵巢癌細胞的轉移能力
英文論文名稱 A novel 5,7-Dihydroxy-3’,4’-Diaminoflavone downregulates HER2 expression and represses metastasis-associated properties in HER2-overexpressing ovarian cancer cells
校院名稱 淡江大學
系所名稱(中) 化學學系碩士班
系所名稱(英) Department of Chemistry
學年度 101
學期 2
出版年 102
研究生中文姓名 鄭欣怡
研究生英文姓名 Hsin-Yi Cheng
學號 600180177
學位類別 碩士
語文別 中文
口試日期 2013-06-21
論文頁數 45頁
口試委員 指導教授-莊子超
中文關鍵字 人類表皮生長因子受體2 
英文關鍵字 HER2 
學科別分類 學科別自然科學化學
中文摘要 類黃酮已經被研究出許多抗癌活性,包括抗增生、促進細胞凋亡、抗血管新生和細胞週期阻斷。約有30%的乳癌和卵巢癌病人有HER2基因放大或是HER2過表現的現象,且HER2過表現和細胞轉移及抗藥性有關。一系列新穎的黃酮類化合物被用來探討其對癌細胞的抗癌作用。我們發現了Cpd3 (5,7-Dihydroxy-3’,4’-Diaminoflavone)在HER2過表現癌細胞中有明顯的抗癌活性,包括抗增生、抗轉移以及促進細胞凋亡。此外,Cpd3可以增加HER2過表現細胞細胞中的HER2降解。這些結果表明,Cpd3可能是透過降低HER2的表現量以抑制HER2過表現細胞的細胞生長。
英文摘要 Flavonoids have been studied for their anti-tumor properties, including anti-proliferative, proapoptotic, anti-angiogenic and cell cycle arrest activities in several cancer cells. Her2 is amplified and/or overexpressed in about 30% of ovarian and breast cancers and is associated with metastasis and drug resistance. A series of novel flavones were used to explore their anticancer effects on cancer cells. We found a 5,7-Dihydroxy-3’,4’-Diaminoflavone, Cpd3, with significant anti-tumor activities in HER2-overexpressing cancer cells, including anti-proliferative, anti-metastatic, and proapoptotic activities. Moreover, Cpd3 could increase the HER2 degradation in HER2-overexpressing cells. These data suggest that cpd3 suppress the HER2-overexpressing cancer cells growth may via down-regulation of HER2.
論文目次 謝誌 I
縮寫表 IV
目錄 V
第一章 緒論 1
第一節HER2/neu 1
1-1 HER2/neu的簡介 1
1-2 HER2和癌症間的關係 3
1-3 HER2的訊號路徑 3
1-4 以HER2為目標的治療方式 4
1-4-1單株抗體 (monoclonal antibodies, mAbs) 5
1-4-2 酪胺酸激酶抑制劑 (tyrosine kinase inhibitors) 6
1-4-3 Hsp90 (Heat shock protein 90) 抑制劑 6
第二節 黃酮類化合物 7
2-1黃酮類的簡介 7
2-2黃酮類和癌症的關係 9
研究動機 11
第二章 材料與方法 12
第一節 材料 12
1-1 試劑 (Reagent) 12
1-2 抗體 (Antibody) 13
第二節 方法 13
第三章 結果 21
第一節實驗結果 21
第二節 實驗圖表 25
第四章 討論 32
第五章 參考資料 34
附錄一 42
附錄二 45
參考文獻 Albanell, Joan, et al. "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4." New Trends in Cancer for the 21st Century. Springer US, 2003. 253-268.

Bazley, L. A., and W. J. Gullick. "The epidermal growth factor receptor family."Endocrine-related cancer 12.Supplement 1 (2005): S17-S27.

Benusiglio, Patrick R. "Focus on ERBB2." (2008): 825-828.

Chan, Richard, et al. "Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development." Development131.22 (2004): 5551-5560.

Chang, Hsueh-Ling, et al. "Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo." Cancer letters 267.1 (2008): 85-95.

Chen, C. Y., G. Chen, and W. Y. Chen. "Molecular simulation of HER2/neu degradation by inhibiting HSP90." JOURNAL-CHINESE CHEMICAL SOCIETY TAIPEI 55.2 (2008): 297.

Chen J, Li Z, Chen AY, Ye X, Luo H, Rankin GO, Chen YC. " Inhibitory effect of baicalin and baicalein on ovarian cancer cells." Int J Mol Sci. 2013 Mar 15;14(3):6012-25

Chiang, Chun-Te, Tzong-Der Way, and Jen-Kun Lin. "Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin." Molecular cancer therapeutics 6.7 (2007): 2127-2138.

Cook, N. C., and St Samman. "Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources." The Journal of Nutritional Biochemistry 7.2 (1996): 66-76.

Coussens, Lisa, et al. "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." Science230.4730 (1985): 1132-1139.

Di Fiore, Pier Paolo, et al. "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells." Science 237.4811 (1987): 178-182.

English, Jessie M., and Melanie H. Cobb. "Pharmacological inhibitors of MAPK pathways." Trends in Pharmacological Sciences 23.1 (2002): 40-45.

Grassi, Davide, Giovambattista Desideri, and Claudio Ferri. "Flavonoids: antioxidants against atherosclerosis." Nutrients 2.8 (2010): 889-902.

Guiu, Severine, et al. "Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy." Journal of oncology 2013 (2013).

Herlaar, Ellen, and Zarin Brown. "p38 MAPK signalling cascades in inflammatory disease." Molecular medicine today 5.10 (1999): 439-447.

Hung, Chao-Ming, et al. "Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells." Journal of agricultural and food chemistry 59.17 (2011): 9683-9690.

Lopez-Lazaro, Miguel. "Distribution and biological activities of the flavonoid luteolin." Mini reviews in medicinal chemistry 9.1 (2009): 31-59.

Le Marchand, Loic. "Cancer preventive effects of flavonoids—a review."Biomedicine & pharmacotherapy 56.6 (2002): 296-301.

Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC,Yu D." 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition." Cancer Cell. 2009 Sep 8;16(3):195-207

Olayioye, Monilola A. "Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members." Breast Cancer Res 3.6 (2001): 385-389.

Mendelsohn, John, and Jose Baselga. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." Journal of clinical oncology 21.14 (2003): 2787-2799.

Murphy, Conleth G., and Shanu Modi. "HER2 breast cancer therapies: a review." Biologics: targets & therapy 3 (2009): 289.

Osaki, M., M. and Oshimura, and H. Ito. "PI3K-Akt pathway: its functions and alterations in human cancer." Apoptosis 9.6 (2004): 667-676.

Prasad, Sahdeo, et al. "Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer." Planta medica 76.11 (2010): 1044-1063.

Prochazkova, D., I. Boušova, and N. Wilhelmova. "Antioxidant and prooxidant properties of flavonoids." Fitoterapia 82.4 (2011): 513-523.

Ren, Wenying, et al. "Flavonoids: promising anticancer agents." Medicinal research reviews 23.4 (2003): 519-534.

Schechter, Alan L., et al. "The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor." Science 229.4717 (1985): 976-978.

Seelinger, Gunter, et al. "Anti-carcinogenic effects of the flavonoid luteolin."Molecules 13.10 (2008): 2628-2651.

Seger, Rony, and Edwin G. Krebs. "The MAPK signaling cascade." The FASEB journal 9.9 (1995): 726-735.

Semba, Kentaro, et al. "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma." Proceedings of the National Academy of Sciences 82.19 (1985): 6497-6501.

Seo, Hye-Sook, et al. "Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells." Molecular and cellular biochemistry 366.1-2 (2012): 319-334.

Soga, Shiro, Shiro Akinaga, and Yukimasa Shiotsu. "Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development." Current pharmaceutical design 19.3 (2013): 366-376.

Solit, David B., et al. "17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts." Clinical cancer research 8.5 (2002): 986-993.

Stancovski, Ilana, et al. "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth." Proceedings of the National Academy of Sciences 88.19 (1991): 8691-8695.

Way, Tzong-Der, Ming-Ching Kao, and Jen-Kun Lin. "Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway." Journal of Biological Chemistry 279.6 (2004): 4479-4489.

Yu, Dihua, and Mien-Chie Hung. "Overexpression of ErbB2 in cancer and ErbB2-targeting strategies." Oncogene 19.53 (2000): 6115.

Yu, Dihua, and Mien-Chie Hung. "The erbB2 gene as a cancer therapeutic target and the tumor-and metastasis-suppressing function of E1A." Cancer and Metastasis Reviews 17.2 (1998): 195-202.

Zhang, Lisha, et al. "Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin." Cancer research 55.17 (1995): 3890-3896.

Zhang, Lisha, et al. "Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties." Oncogene 16.22 (1998): 2855-2863.

Zhu, Yi, et al. "Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells." Cancer cell international 13.1 (2013): 54.

  • 同意紙本無償授權給館內讀者為學術之目的重製使用,於2016-07-30公開。
  • 同意授權瀏覽/列印電子全文服務,於2016-07-30起公開。

  • 若您有任何疑問,請與我們聯絡!
    圖書館: 請來電 (02)2621-5656 轉 2487 或 來信 dss@mail.tku.edu.tw